Tablet formulation of Famotidine-loaded P-gp inhibiting nanoparticles using PLA-g-PEG grafted polymer

References

• Abebe A, Akseli I, Sprockel O, Kottala N, Cuitino AM. 2014. Review of bilayer tablet technology. Int J Pharm. 461:549–558.
   PubMedGoogle Scholar
• Akhtar N, Ahad A, Khar RK, Jaggi M, Aqil M, Iqbal Z, Ahmad FJ, Talegaonkar S. 2011. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Patents. 21:561–576.
   PubMed Web of Science ®Google Scholar
• Aulton ME. 2007. Aulton’s pharmaceutics: the design and manufacture of medicines. 3rd ed. Edinburgh (NY): Churchill Livingstone.
   Google Scholar
• Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. 2002. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release. 79:123–135.
   PubMed Web of Science ®Google Scholar
• Bala I, Hariharan S, Kumar M. 2004. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 21:387–422.
   PubMed Web of Science ®Google Scholar
• Ballester-Rodes M, Palomo-Nicolau FE, Palomo-Coll AL. Famotidine polymorphic form and preparation thereof. Google Patents; 1991.
   Google Scholar
• Baseer A, Hassan F, Hassan SF, Jabeen S, Israr F, Murtaza G, Haque N. 2013. Physico-chemical comparison of famotidine tablets prepared via dry granulation and direct compression techniques. Pak J Pharm Sci. 26:439–443.
   PubMed Web of Science ®Google Scholar
• Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R, Ravi Kumar MNV. 2005. Pharmaceutical aspects of polymeric nanoparticles for oral drug delivery. J Biomed Nanotechnol. 1:235–258.
   Web of Science ®Google Scholar
• Bourdet D, Thakker D. 2006. Saturable absorptive transport of the hydrophilic organic cation ranitidine in caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein. Pharm Res. 23:1165–1177.
   PubMed Web of Science ®Google Scholar
• Camboìn A, Brea J, Loza MI, Alvarez-Lorenzo C, Concheiro A, Barbosa S, Taboada P, Mosquera V. 2013. Cytocompatibility and P-glycoprotein inhibition of block copolymers: structure–activity relationship. Mol Pharm. 10:3232–3241.
   PubMedGoogle Scholar
• Choi K-M, Choi M-C, Han D-H, Park T-S, Ha C-S. 2013. Plasticization of poly(lactic acid) (PLA) through chemical grafting of poly (ethylene glycol) (PEG) via in situ reactive blending. Eur Polym J. 49:2356–2364.
   Web of Science ®Google Scholar
• Dolenc A, Kristl J, Baumgartner S, Planinsek O. 2009. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 376:204–212.
   PubMed Web of Science ®Google Scholar
• Elmowafy E, Awad G, Mansour S, El-Shamy A. 2008. Release mechanisms behind polysaccharides-based famotidine controlled release matrix tablets. AAPS PharmSciTech. 9:1230–1239.
   PubMed Web of Science ®Google Scholar
• Essa S, Rabanel JM, Hildgen P. 2010. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(d,l-lactide) (PLA) based nanoparticles. Eur J Pharm Biopharm. 75:96–106.
   PubMed Web of Science ®Google Scholar
• Estudante M, Morais JG, Soveral G, Benet LZ. 2013. Intestinal drug transporters: an overview. Adv Drug Deliv Rev. 65:1340–1356.
   PubMed Web of Science ®Google Scholar
• Ferenczy GG, Parkanyi L, Angyan JG, Kalman A, Hegedus B. 2000. Crystal and electronic structure of two polymorphic modifications of famotidine. An experimental and theoretical study. J Mol Struct (Theochem). 503:73–79.
   Web of Science ®Google Scholar
• Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller RH. 2000. Stealth corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B: Biointerfaces. 18:301–313.
   PubMed Web of Science ®Google Scholar
• Gupta U, Agashe HB, Jain NK. 2007. Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes. J Pharm Pharmaceut Sci. 10:358–367.
   PubMed Web of Science ®Google Scholar
• Hassouna F, Raquez J-M, Addiego F, Dubois P, Toniazzo V, Ruch D. 2011. New approach on the development of plasticized polylactide (PLA): grafting of poly(ethylene glycol) (PEG) via reactive extrusion. Eur Polym J. 47:2134–2144.
   Web of Science ®Google Scholar
• Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. 2005. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 299:167–177.
   PubMed Web of Science ®Google Scholar
• Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. 2004. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins – introduction. Pflugers Arch. 447:465–468.
   PubMed Web of Science ®Google Scholar
• Hugger ED, Cole CJ, Raub TJ, Burton PS, Borchardt RT. 2003. Automated analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro. J Pharm Sci. 92:21–26.
   PubMed Web of Science ®Google Scholar
• Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. 2002. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci. 91:1991–2002.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Hombach J, Matuszczak B, Bernkop-Schnurch A. 2010. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J Control Release. 147:62–69.
   PubMed Web of Science ®Google Scholar
• Jiang T, Han N, Zhao B, Xie Y, Wang S. 2012. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Drug Dev Ind Pharm. 38:1230–1239.
   PubMed Web of Science ®Google Scholar
• Johnson BM, Charman WN, Porter CJH. 2002. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on PGlycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS J. 4:13.
   Google Scholar
• Kin-Kai H, Giesing DH, Hurst GH. US6451815. Aventis Pharmaceuticals, Inc. Method of enhancing bioavailability of fexofenadine and its derivatives. US6451815. 2002.
   Google Scholar
• Kleinebudde P. 2004. Roll compaction/dry granulation: pharmaceutical applications. Eur J Pharm Biopharm. 58:317–326.
   PubMed Web of Science ®Google Scholar
• Krogh C. 1983. Compendium of pharmaceuticals and specialties. Can Med Assoc J. 129:928
   PubMed Web of Science ®Google Scholar
• Lee K, Thakker DR. 1999. Saturable transport of H2-antagonists ranitidine and famotidine across caco-2 cell monolayers. J Pharm Sci. 88:680–687.
   PubMed Web of Science ®Google Scholar
• Leuenberger H, Lanz M. 2005. Pharmaceutical powder technology from art to science: the challenge of the FDA’s Process Analytical Technology initiative. Adv Powder Technol. 16:3–25.
   Web of Science ®Google Scholar
• Li Q, Rudolph V, Weigl B, Earl A. 2004. Interparticle van der Waals force in powder flowability and compactibility. Int J Pharm. 280:77–93.
   PubMed Web of Science ®Google Scholar
• Liu P, Rong X, Laru J, van Veen B, Kiesvaara J, Hirvonen J, Laaksonen T, Peltonen L. 2011. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int J Pharm. 411:215–222.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chiu GNC. 2013. Dual-functionalized PAMAM dendrimers with improved P-glycoprotein inhibition and tight junction modulating effect. Biomacromolecules. 14:4226–4235.
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. 2001a. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J Biol Chem. 276:14972–14979.
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. 2001b. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J Biol Chem. 276:36877–36880.
   PubMed Web of Science ®Google Scholar
• Lu J, Wang X-J, Yang X, Ching C-B. 2007. Polymorphism and crystallization of famotidine. Cryst Growth Des. 7:1590–1598.
   Web of Science ®Google Scholar
• Lu J, Wang XJ, Yang X, Ching CB. 2008. Notice of retraction and apology. J Pharm Sci. 97:1629.
   PubMedGoogle Scholar
• Rabanel JM, Aoun V, Elkin I, Mokhtar M, Hildgen P. 2012. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. Curr Med Chem. 19:3070–3102.
   PubMed Web of Science ®Google Scholar
• Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Ishiguro T, Hirayama F, Uekama K, Otagiri M. 2010. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-beta-CyD/povidone K30 complexation approach. J Pharm Sci. 99:4285–4294.
   PubMed Web of Science ®Google Scholar
• McDevitt CA, Callaghan R. 2007. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther. 113:429–441.
   PubMed Web of Science ®Google Scholar
• Mckenna A, Mccafferty DF. 1982. Effect on particle size on the compaction mechanism and tensile strength of tablets. J Pharm Pharmacol. 34:347–351.
   PubMed Web of Science ®Google Scholar
• McNally GP, Roche EJ. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders. Google Patents; 1997.
   Google Scholar
• Mert O, Lai SK, Ensign L, Yang M, Wang Y-Y, Wood J, Hanes J. 2012. A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. J Control Release. 157:455–460.
   PubMed Web of Science ®Google Scholar
• Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. 2007. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release. 119:77–85.
   PubMed Web of Science ®Google Scholar
• Mokhtar M, Gosselin PM, Lacasse F, Hildgen P. 2017. Design of PEG-grafted-PLA nanoparticles as oral permeability enhancer for P-gp substrate drug model Famotidine. J Microencapsul. 34:91–103.
   PubMed Web of Science ®Google Scholar
• Morakul B, Suksiriworapong J, Leanpolchareanchai J, Junyaprasert VB. 2013. Precipitation–lyophilization–homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. Int J Pharm Special Sect: Formulat Better Med Child. 457:187–196.
   Google Scholar
• More PK, Khomane KS, Bansal AK. 2013. Flow and compaction behaviour of ultrafine coated ibuprofen. Int J Pharm. 441:527–534.
   PubMedGoogle Scholar
• Nadeau V, Leclair G, Sant S, Rabanel J-M, Quesnel R, Hildgen P. 2005. Synthesis of new versatile functionalized polyesters for biomedical applications. Polymer. 46:11263–11272.
   Web of Science ®Google Scholar
• Owens DE, Peppas NA. 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–102.
   PubMed Web of Science ®Google Scholar
• Panakanti R, Narang AS. 2012. Impact of excipient interactions on drug bioavailability from solid dosage forms. Pharm Res. 29:2639–2659.
   PubMed Web of Science ®Google Scholar
• Parrott EL. 1981. Densification of powders by concavo-convex roller compactor. J Pharm Sci. 70:288–291.
   PubMed Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. 2004. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 56:827–840.
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Quinn ME. 2009. Handbook of pharmaceutical excipients. 6th ed. London/ Chicago, Washington, DC: Pharmaceutical Press, American Pharmacists Association.
   Google Scholar
• Rozehnal V, Nakai D, Hoepner U, Fischer T, Kamiyama E, Takahashi M, Yasuda S, Mueller J. 2012. Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs. Eur J Pharm Sci. 46:367–373.
   PubMed Web of Science ®Google Scholar
• Sahoo NG, Kakran M, Shaal LA, Li L, Muller RH, Pal M, Tan LP. 2011. Preparation and characterization of quercetin nanocrystals. J Pharm Sci. 100:2379–2390.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Panyam J, Prabha S, Labhasetwar V. 2002. Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82:105–114.
   PubMed Web of Science ®Google Scholar
• Sandler N, Lammens RF. 2011. Pneumatic dry granulation: potential to improve roller compaction technology in drug manufacture. Expert Opin Drug Deliv. 8:225–236.
   PubMed Web of Science ®Google Scholar
• Sant S, Poulin S, Hildgen P. 2008. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles. J Biomed Mater Res A. 87:885–895.
   PubMed Web of Science ®Google Scholar
• Sáska Z, Dredán J, Luhn O, Balogh E, Shafir G, Antal I. 2011. Evaluation of the impact of mixing speed on the compressibility and compactibility of paracetamol-isomalt containing granules with factorial design. Powder Technol. 213:132–140.
   Web of Science ®Google Scholar
• Sepassi S, Goodwin DJ, Drake AF, Holland S, Leonard G, Martini L, Lawrence MJ. 2007. Effect of polymer molecular weight on the production of drug nanoparticles. J Pharm Sci. 96:2655–2666.
   PubMed Web of Science ®Google Scholar
• Shen Q, Lin Y, Handa T, Doi M, Sugie M, Wakayama K, Okada N, Fujita T, Yamamoto A. 2006. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 313:49–56.
   PubMed Web of Science ®Google Scholar
• Shilpa S, Ve´ronique N, Hildgen P. 2005. Effect of porosity on the release kinetics of propafenone-loaded PEG-g-PLA nanoparticles. J Control Release. 107:203–214.
   PubMed Web of Science ®Google Scholar
• Shoaib M, Al Sabah Siddiqi S, Yousuf R, Zaheer K, Hanif M, Rehana S, Jabeen S. 2010. Development and evaluation of hydrophilic colloid matrix of famotidine tablets. AAPS PharmSciTech. 11:708–718.
   PubMed Web of Science ®Google Scholar
• Teng Y, Qiu Z, Wen H. 2009. Systematical approach of formulation and process development using roller compaction. Eur J Pharm Biopharm. 73:219–229.
   PubMed Web of Science ®Google Scholar
• USP. 2014. United States Pharmacopeia and National Formulary (USP-NF). Rockville, MD, USA.
   Google Scholar
• Wehrung D, Geldenhuys WJ, Oyewumi MO. 2012. Effects of gelucire content on stability, macrophage interaction and blood circulation of nanoparticles engineered from nanoemulsions. Colloids Surf B: Biointerfaces. 94:259–265.
   PubMed Web of Science ®Google Scholar
• Yoncheva K, Lizarraga E, Irache JM. 2005. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. Eur J Pharm Sci. 24:411–419.
   PubMed Web of Science ®Google Scholar
• Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrudea P, Vignerona C. 1998. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release 50:31–40.
   PubMed Web of Science ®Google Scholar